Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Medical College of Wisconsin, Milwaukee, Wisconsin; RPRD (Right Patient Right Drug) Diagnostics, LLC, Wauwatosa, Wisconsin.
J Mol Diagn. 2019 Nov;21(6):1034-1052. doi: 10.1016/j.jmoldx.2019.06.007. Epub 2019 Aug 9.
Pharmacogenetic testing increasingly is available from clinical and research laboratories. However, only a limited number of quality control and other reference materials currently are available for the complex rearrangements and rare variants that occur in the CYP2D6 gene. To address this need, the Division of Laboratory Systems, CDC-based Genetic Testing Reference Material Coordination Program, in collaboration with members of the pharmacogenetic testing and research communities and the Coriell Cell Repositories (Camden, NJ), has characterized 179 DNA samples derived from Coriell cell lines. Testing included the recharacterization of 137 genomic DNAs that were genotyped in previous Genetic Testing Reference Material Coordination Program studies and 42 additional samples that had not been characterized previously. DNA samples were distributed to volunteer testing laboratories for genotyping using a variety of commercially available and laboratory-developed tests. These publicly available samples will support the quality-assurance and quality-control programs of clinical laboratories performing CYP2D6 testing.
越来越多的临床和研究实验室提供药物遗传学检测。然而,目前只有有限数量的质量控制和其他参考材料可用于 CYP2D6 基因中发生的复杂重排和罕见变异。为满足这一需求,疾病预防控制中心基于实验室系统的遗传检测参考材料协调计划与药物遗传学检测和研究界成员以及科利尔细胞库(新泽西州卡姆登)合作,对来自科利尔细胞系的 179 个 DNA 样本进行了特征描述。检测包括对先前遗传检测参考材料协调计划研究中进行基因分型的 137 个基因组 DNA 的重新特征描述,以及对以前未进行特征描述的 42 个额外样本的检测。将 DNA 样本分发给志愿者检测实验室,使用各种市售和实验室开发的检测方法进行基因分型。这些公开可用的样本将支持进行 CYP2D6 检测的临床实验室的质量保证和质量控制计划。